Is 'Bedside Medicine' Returning to Oncology?
نویسندگان
چکیده
منابع مشابه
Reality Shock Revisited: Returning to the Bedside
ID: 621 Reality Shock Revisited: Returning to the Bedside Author Information: Authors List: Presenting Author: Joyce Burr Presenting Author: Joyce P. Burr Address: 4215 79th Street Vero Beach, Florida 32967 USA Ph: none Fax: Email: [email protected] Institution: University of Central Florida Abstract InformationInformation Presentation Preference: SNRS Student Poster Presentation Abstract Cat...
متن کاملBringing evidence-based medicine to the bedside.
E medicine (EBM), the philosophical origins of which extend back to the mid-19th century and earlier, remains a contemporary topic for clinicians.1 Despite its ancient origins, EBM remains a young discipline and its positive impacts are just beginning to be validated, and it continues to evolve.1 Evidence-based medicine is defined as “the conscientious, explicit, and judicious use of current be...
متن کاملPhysical oncology: a bench-to-bedside quantitative and predictive approach.
Cancer models relating basic science to clinical care in oncology may fail to address the nuances of tumor behavior and therapy, as in the case, discussed herein, of the complex multiscale dynamics leading to the often-observed enhanced invasiveness, paradoxically induced by the very antiangiogenic therapy designed to destroy the tumor. Studies would benefit from approaches that quantitatively ...
متن کاملClinical Medicine Insights: Oncology
We report a 41 year old male with sickle cell disease who developed a myelodysplastic syndrome and acute myeloid leukemia with complex karyotype involving chromosomes 5, 7 and 17 after 15 years of hydroxyurea treatment. He responded poorly to induction chemotherapy with cytarabine/idarubicin followed by high dose cytarabine and succumbed to neutropenic sepsis. Multiple systematic reviews, obser...
متن کاملClinical Medicine Insights: Oncology
Trastuzumab, a humanized mouse monoclonal antibody directed against HER2 (Human Epidermal Growth Factor Receptor 2), is currently a keystone in the treatment of breast cancer. Meanwhile, trastuzumab has been validated for use in other types of cancer too. But the data on HER2 expression in colorectal cancer are ambiguous, with reported overexpression of HER2 varying between zero and 84%. In thi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Acta Oncologica
سال: 2000
ISSN: 0284-186X,1651-226X
DOI: 10.1080/028418600430905